Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
SVRA compared with GLUE: revenue, margins and what each company keeps, and the suppliers and customers both name
SVRA
Savara Inc
Change
Mkt cap
Revenue
Revenue
GLUE
Monte Rosa Therapeutics, Inc.
Change
Mkt cap
Revenue
Revenue
vs
Compare
SVRA
Savara Inc
vs
GLUE
Monte Rosa Therapeutics, Inc.
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Revenue flow
Desk
News
Calendar
Saved
Search
SVRA
Savara Inc
Change
4.60
▼
−3.15%
Mkt cap
$975.9M
Revenue
—
Revenue
—
GLUE
Monte Rosa Therapeutics, Inc.
Change
10.64
▲
+2.23%
Regular session
Nov 4 '26
Mkt cap
$888.1M
Revenue
$9M
Q2 FY26
Revenue
$124M
FY25
vs
Compare
Regular session
Nov 4 '26
SVRA
Savara Inc
vs
GLUE
Monte Rosa Therapeutics, Inc.
4.60
▼
−3.15%
Price
10.64
▲
+2.23%
$975.9M
Mkt cap
$888.1M
—
Revenue
$9M
Q2 FY26
—
Revenue
$124M
FY25
Change
Change
SVRA
4.60
▼
−3.15%
vs
GLUE
10.64
▲
+2.23%
Regular session
Nov 4 '26
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Price
Supply-chain overlap
Revenue flow
SVRA: latest quarter not drawable. GLUE: latest quarter is a loss; flow not drawable.
Method
›
Supply-chain overlap
direct ties · both sides
Sources
›
direct ties · both sides
Only SVRA
7
—
FUJIFILM Diosynth Biotechnologies
unlisted
supplier
—
GEMA Biotech
unlisted
supplier
—
Parexel
unlisted
supplier
—
PARI Pharma GmbH
unlisted
supplier
3 more · SVRA chain
›
Shared
0
No disclosed counterparties: GLUE.
Only GLUE
0
None
Role chip = supplier or customer
—
= no ticker (unlisted)
Source: SEC EDGAR
Price
rebased to 0%
1D
1W
1M
3M
YTD
1Y
5Y
1D
1W
1M
3M
YTD
1Y
5Y
SVRA, solid
GLUE, dashed